Comments on: Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study
International Journal of Rheumatic Diseases · 2026-11 · 29 (11)
DOI: 10.1111/1756-185x.70964 ↗Kurz gefasst
Leserbrief in der Zeitschrift International Journal of Rheumatic Diseases, online erschienen am 09.11.2026. Verfasst von Abbas Iqbal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Royal College of Surgeons Ireland, Dublin, Ireland. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
Data sharing does not apply to this article as no datasets were generated during the current study; all data were sourced from published literature.
Autor:innen und Institutionen
- Royal College of Surgeons Ireland, Dublin, Ireland.
- Bannu Medical College, Bannu, Khyber Pakhtunkhwa, Pakistan.
- Northwest School of Medicine, Peshawar, Pakistan.
ORCID-Profile: Abbas Iqbal, Abubakar Afzal, Zaib Un Nisa
Zitieren
APA
Iqbal, A., Afzal, A., & Nisa, Z. U. (2026). Comments on: Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study. International Journal of Rheumatic Diseases, 29(11). https://doi.org/10.1111/1756-185x.70964
Vancouver
Iqbal A, Afzal A, Nisa ZU. Comments on: Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study. International Journal of Rheumatic Diseases. 2026;29(11). doi:10.1111/1756-185x.70964
BibTeX
@article{Iqbal2026,
author = {Iqbal, Abbas and Afzal, Abubakar and Nisa, Zaib Un},
title = {Comments on: Real‐World Data of Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Taiwanese Patients With Rheumatoid Arthritis From a Drug‐Based Cohort Study},
journal = {International Journal of Rheumatic Diseases},
year = {2026},
volume = {29},
number = {11},
doi = {10.1111/1756-185x.70964}
}
EUVIMED